IMPACT OF INCLUSION OF FINERENONE IN THE BURDEN OF CHRONIC KIDNEY DISEASE (CKD) IN TYPE 2 DIABETES (T2D) IN COLOMBIA

被引：0
|
作者：
Lopez-Cabra, C. [1 ]
Rodriguez, A. D. [2 ]
Mayorga, Mogollon W. [2 ]
Zuluaga, J. R. [3 ]
Patino, A. [1 ]
Herran, S. E. [3 ]
Marrugo, R. [3 ]
机构：
[1] Bayer, Bogota, Cun, Colombia
[2] Numeris, Bogota, Colombia
[3] Bayer, Bogota, Colombia
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE425
引用
收藏
页码：S137 / S137
页数：1
相关论文
共 50 条
  • [21] Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)
    Li, Jingwei
    Neal, Bruce
    Heerspink, Hiddo L.
    Arnott, Clare
    Cannon, Christopher
    Agarwal, Rajiv
    Bakris, George
    Charytan, David M.
    de Zeeuw, Dick
    Greene, Tom
    Levin, Adeera
    Oh, Richard
    Pollock, Carol A.
    Wheeler, David C.
    Yavin, Yshai
    Zhang, Hong
    Zinman, Bernard
    Di Tanna, Gian Luca
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    Jardine, Meg
    DIABETES, 2020, 69
  • [22] Real-World Effectiveness of Finerenone in Chinese Patients with Type 2 Diabetes Mellitus (T2MD) and Chronic Kidney Disease (CKD)
    Li, Ang
    Gao, Ying
    Guo, Xiaohui
    Zhang, Junqing
    DIABETES, 2024, 73
  • [23] Level of Glycemic Control in Type 2 Diabetes (T2D) Patients with Established Cardiovascular Disease (eCVD) or Chronic Kidney Disease (CKD) Prescribed an SGLT2i
    Iglay, Kristy
    Bansal, Neha
    Gulati, Tania
    Hannachi, Hakima
    Fernandes, Gail
    Rajpathak, Swapnil
    DIABETES, 2019, 68
  • [24] Diabetic Kidney Disease (DKD) in UK Patients With Type 2 Diabetes (T2D)
    Ruzafa, Javier Cid
    Paczkowski, Rosirene
    Boye, Kristina S.
    Di Tanna, Gian Luca
    Sheetz, Matthew J.
    Donaldson, Robert
    Breyer, Matthew D.
    Neasham, David
    Voelker, James R.
    DIABETES, 2013, 62 : A397 - A397
  • [25] FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
    Pochopien, Michal T.
    Cherney, David Z., I
    Folkerts, Kerstin
    Levy, Pierre
    Millier, Aurelie
    Morris, Stephen
    Roy-Chaudhury, Prabir
    Sullivan, Sean D.
    Mernagh, Paul
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (20): : S375 - S382
  • [26] Finerenone for Patients With CKD and Type 2 Diabetes
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (08): : 713 - 713
  • [27] Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
    Filippatos, Gerasimos
    Anker, Stefan D.
    Agarwal, Rajiv
    Pitt, Bertram
    Rossing, Peter
    Ruilope, Luis M.
    Kolkhof, Peter
    Schloemer, Patrick
    Tornus, Ingo
    Joseph, Amer
    Bakris, George L.
    CIRCULATION, 2020, 142 (24) : E470 - E470
  • [28] Chronic Kidney Disease (CKD) in US Adults with Type 2 Diabetes (T2D) and Cardiovascular Diseases (CVD)-A National Estimate of Prevalence by KDIGO 2012 Classification
    Wang, Tongtong
    Xi, Yuzhi
    Lubwama, Robert N.
    Koro, Carol
    DIABETES, 2018, 67
  • [29] Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
    Filippatos, Gerasimos
    Anker, Stefan D.
    Bakris, George L.
    Rossing, Peter
    Ruilope, Luis M.
    Coats, Andrew J. S.
    von Haehling, Stephan
    Ponikowski, Piotr
    Rosano, Giuseppe M. C.
    Brinker, Meike
    Farjat, Alfredo E.
    Roberts, Luke
    Pitt, Bertram
    ESC HEART FAILURE, 2025, 12 (01): : 185 - 188
  • [30] Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
    Filippatos, Gerasimos
    Anker, Stefan D.
    Agarwal, Rajiv
    Pitt, Bertram
    Ruilope, Luis M.
    Rossing, Peter
    Kolkhof, Peter
    Schloemer, Patrick
    Tornus, Ingo
    Joseph, Amer
    Bakris, George L.
    CIRCULATION, 2021, 143 (06) : 540 - 552
12345